SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-004482
Filing Date
2021-11-15
Accepted
2021-11-15 08:04:13
Documents
14
Period of Report
2021-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K impl-20211115.htm   iXBRL 8-K 66094
2 EX-99.1 impl-ex99_1.htm EX-99.1 518815
3 GRAPHIC img155103045_0.jpg GRAPHIC 89574
  Complete submission text file 0000950170-21-004482.txt   864345

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20211115_pre.xml EX-101.PRE 11969
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20211115_lab.xml EX-101.LAB 19080
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20211115.xsd EX-101.SCH 2477
7 EXTRACTED XBRL INSTANCE DOCUMENT impl-20211115_htm.xml XML 5106
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL NEUROPHARMA INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 211406473
SIC: 2834 Pharmaceutical Preparations